Fig. 2

The effects of canagliflozin on the glycated hemoglobin (HbA1c) level and epicardial fat thickness. Values before initiating therapy and after 3 or 6 months are compared. a Canagliflozin decreased the HbA1c level at 6 months of therapy. b Canagliflozin decreased the epicardial fat tissue thickness at 3 and 6 months of therapy. *P < 0.05, **P < 0.01, and ***P < 0.001, compared to values before initiating therapy